Edgewise Therapeutics (EWTX) Enterprise Value (2021 - 2026)

Edgewise Therapeutics has reported Enterprise Value for 7 years, with the latest figure at -$33.2 million in Q1 2026.

• Quarterly Enterprise Value rose 33.47% year-over-year to -$33.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$33.2 million (up 33.47% YoY) and the FY2025 annual result came in at -$61.1 million, down 46.76% from the prior year.
• Enterprise Value grew to -$33.2 million in Q1 2026 per EWTX's latest filing, from -$61.1 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$22.0 million in Q4 2022 and troughed at -$563.3 million in Q3 2025.
• A 5-year average of -$145.6 million and a median of -$48.2 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 1394.37% in 2024, then soared 90.63% in 2025.
• Over 5 years, Enterprise Value stood at -$22.0 million in 2022, then plunged by 291.47% to -$86.1 million in 2023, then soared by 51.61% to -$41.7 million in 2024, then sank by 46.76% to -$61.1 million in 2025, then soared by 45.69% to -$33.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$33.2 million, -$61.1 million, and -$563.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.